Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582205 | 0.91 | CSNK2A2 (0.52) | ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL5582212 | 0.89 | CSNK2A1 (0.49) | ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL5582252 | 0.88 | VCP (0.44) | ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL5582245 | 0.86 | CSNK2A1 (0.51) | CASRADORA1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5582210 | 0.85 | CSNK2A1 (0.51) | ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL5582126 | 0.83 | PDE5A (0.43) | VNN1CASRADORA1HTT | |
| SCHEMBL5582238 | 0.83 | MAP4K4 (0.52) | ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL5581995 | 0.82 | CSNK2A1 (0.50) | ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL5582194 | 0.82 | CSNK2A1 (0.48) | ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL5582330 | 0.82 | CSNK2A1 (0.48) | CSNK2A2CSNK2BCSNK2A1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | VNN1 4521/4885CASR 1544/4885ADORA1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.